Guggenheim raised the firm's price target on Assembly Biosciences (ASMB) to $43 from $39 and keeps a Buy rating on the shares. The firm is updating its Assembly model to reflect the earlier Gilead (GILD) opt-in, the company's Q4 results and "increased enthusiasm" for ABI-5366 and ABI-1179 now that they have both demonstrated "striking" over 90% reductions in viral shedding and genital lesions, the analyst tells investors.
